Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. All medicinal products in the EU are subject to a strict testing and assessment of their quality, efficacy and safety before being authorized. Once placed on the market they continue to be monitored so to assure that any aspect which could impact the safety profile of a medicine is detected and assessed and that necessary measures are taken.
To meet our responsibilities and obligations as required by current legislation, Leriva has developed a pharmacovigilance system to monitor the safety of the medicines we market. Regardless of whether you are a health care professional or patient, by reporting a suspected adverse event, you actively contribute to the ongoing monitoring of the safety and quality of our medicinal products.
Ιf you wish to report a suspected adverse event related to our medicinal products, please contact us:
By phone: 210 61 99 886 – press 5 (24/7 availability)
By e-mail: pharmacovigilance@leriva.com
All information collected during the reporting of an adverse reaction is confidential and anonymized, regarding both the reporter and the patient.
To meet our responsibilities and obligations as required by current legislation, Leriva has developed a pharmacovigilance system to monitor the safety of the medicines we market. Regardless of whether you are a health care professional or patient, by reporting a suspected adverse event, you actively contribute to the ongoing monitoring of the safety and quality of our medicinal products.
Ιf you wish to report a suspected adverse event related to our medicinal products, please contact us:
By phone: 210 61 99 886 – press 5 (24/7 availability)
By e-mail: pharmacovigilance@leriva.com
All information collected during the reporting of an adverse reaction is confidential and anonymized, regarding both the reporter and the patient.